Eleven Therapeutics Appoints Prominent Biopharma Leader Dr. Iris Grossman as Chief Strategic Officer

Eleven Therapeutics
3 min readFeb 10, 2022


Dr. Grossman leverages extensive experience in translational science, human genomics, and drug R&D to advance Eleven’s mission

Sep 7th, 2021

TEL AVIV, ISRAEL and BOSTON, US — Eleven Therapeutics, a biotechnology company leading the Artificial Intelligence revolution in nucleic acid therapies, announced today the appointment of Dr. Iris Grossman as its Chief Strategic Officer. Dr. Grossman, a renowned leader in personalised medicine, brings over twenty years of experience in biotechnology and drug development, from Big Pharma to start-ups. Her expertise spans research, development, and market positioning, focusing on the intersection of deep scientific insights and unmet patient needs.

Dr. Grossman has been a pioneer in the application of personalised medicine principles into the entire continuum of drug discovery and development. The portfolios she managed span a wide variety of therapeutic areas and modalities, with an emphasis on the integration of deep scientific insights, clinico-genomic patient data and sophisticated analysis approaches for the purpose of developing therapeutics and diagnostics that better patients’ lives. Previous to her new role at Eleven, Dr. Grossman served as Chief Scientific Officer at biotechnology companies Amide Technologies and CAMP4 Therapeutics, and beforehand as VP, Head of Early Stage Clinical Development at Teva Pharmaceuticals. Dr. Grossman holds a PhD from the Technion — Israel Institute of Technology (in conjunction with the Weizmann Institute of Science), a post-doc fellowship from Duke University, and a HealthTech fellowship from Harvard Business School.

“We are delighted to welcome Iris to our management team,” said Prof. Yaniv Erlich, Co-Founder and CEO of Eleven Therapeutics. “Dr. Grossman’s expertise in translational medicine will expand Eleven’s strategic growth and drive advancement in our fields of research and development on a broad scale.”

“I am thrilled to join the talented team at Eleven and to direct my passions and experience towards some of the most pressing medical challenges of our time,” said Dr. Grossman. “Eleven Therapeutics is engaged in research that I care about deeply, led by an unbeatable team, and following an approach that is groundbreaking. I look forward to plugging in and offering my R&D expertise and strategic leadership as, together, we accelerate the development of revolutionary treatments and prophylactics for respiratory diseases, and beyond.”

Through recent grants from the Bill & Melinda Gates Foundation and Innovate UK, Eleven has been developing and testing novel intranasal siRNA cocktails against respiratory pathogens. The company’s work is powered by its proprietary massively parallel bio-engineered screening platform, Sens.AI.

About Eleven Therapeutics

Eleven Therapeutics ushers in the next generation of RNAi therapeutics by combining artificial intelligence (AI), massively parallel functional assays, and combinatorial chemistry. Its flagship invention features a new modality, dubbed SCSI-RNA™ (single-chassis, small interfering RNA), a fully programmable molecule, rationally designed to address the delivery, durability, and efficacy challenges of any disease and biological target of interest. Founded in 2020 by a group of globally-leading, interdisciplinary scientists, Eleven Therapeutics brings new RNAi therapeutics for patients in need by capitalising on some of the world’s best pools of talent through its three collaborative hubs — in Cambridge, UK; Boston, U.S.; and Tel Aviv, Israel. Eleven is currently focusing its development pipeline on siRNA treatments for a range of respiratory diseases. To learn more, visit www.eleventx.com.


Eleven Therapeutics

Prof. Yaniv Erlich
Chief Executive Officer and Co-Founder
Email: yaniv@eleventx.com

Dr. Iris Grossman
Chief Strategy Officer
Email: iris@eleventx.com